Regentis Biomaterials (RGNT) has obtained approval from the European Notified Body to manufacture its knee cartilage repair product GelrinC using its next-generation solvent-free manufacturing process, the company said Wednesday.
The manufacturing process increases production yield fivefold and improves efficiency and scalability, the company said.
Regentis prepares to commercially launch the product in Europe, it said.
Price: 2.59, Change: +0.09, Percent Change: +3.56